Kriya Therapeutics, Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals

Other Names/Subsidiaries

  • Redpin Therapeutics, Inc.
  • Tramontane Therapeutics
  • Warden Bio
See more in Biomedtracker

Latest on Kriya Therapeutics, Inc.

Scrip

Deal Watch: Bayer Ties Up With Twist On Optimization Of Antibody Discovery

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bayer, Twist Collaboration Gives German

Scrip

Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

 
• By Joseph Haas and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Moderna, Immatics Pair Their Approaches

Scrip

Finance Watch: ADARx Raises $200m, Alltrna Garners $109m To Fund RNA Medicines

 
• By Mandy Jackson

Two companies with different approaches to RNA medicines announced venture capital mega-rounds of $100m or more on 9 August – ADARx Pharmaceuticals, Inc. with a $200m series C financing and Alltrna

Scrip

Finance Watch: Kriya Adds $150m-Plus To Series C As It Gets Closer To The Clinic

 
• By Mandy Jackson

Kriya Therapeutics, Inc. raised a $270m series C round in May 2022 with plans to take its first gene therapy candidates into the clinic in 2023. Now that the company has added more than $150m to that